Cargando…
Current Progress in Cancer Treatment Using Nanomaterials
The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330335/ https://www.ncbi.nlm.nih.gov/pubmed/35912195 http://dx.doi.org/10.3389/fonc.2022.930125 |
_version_ | 1784758135685120000 |
---|---|
author | Zhu, Ruirui Zhang, Fangyuan Peng, Yudong Xie, Tian Wang, Yi Lan, Yin |
author_facet | Zhu, Ruirui Zhang, Fangyuan Peng, Yudong Xie, Tian Wang, Yi Lan, Yin |
author_sort | Zhu, Ruirui |
collection | PubMed |
description | The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size have special optical, magnetic, and electrical characteristics. Nanomaterials have been fabricated for cancer treatments to overcome cytotoxicity and low specificity, and improve drug capacity and bioavailability. Despite the increasing number of related studies, few nanodrugs have been approved for clinical use. To improve translation of these materials, studies of targeted drug delivery using nanocarriers are needed. Cytotoxicity, enhanced permeability and retention effects, and the protective role of the protein corona remain to be addressed. This mini-review summarizes new nanomaterials manufactured in studies and in clinical use, analyses current barriers preventing their translation to clinical use, and describes the effective application of nanomaterials in cancer treatment. |
format | Online Article Text |
id | pubmed-9330335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93303352022-07-29 Current Progress in Cancer Treatment Using Nanomaterials Zhu, Ruirui Zhang, Fangyuan Peng, Yudong Xie, Tian Wang, Yi Lan, Yin Front Oncol Oncology The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size have special optical, magnetic, and electrical characteristics. Nanomaterials have been fabricated for cancer treatments to overcome cytotoxicity and low specificity, and improve drug capacity and bioavailability. Despite the increasing number of related studies, few nanodrugs have been approved for clinical use. To improve translation of these materials, studies of targeted drug delivery using nanocarriers are needed. Cytotoxicity, enhanced permeability and retention effects, and the protective role of the protein corona remain to be addressed. This mini-review summarizes new nanomaterials manufactured in studies and in clinical use, analyses current barriers preventing their translation to clinical use, and describes the effective application of nanomaterials in cancer treatment. Frontiers Media S.A. 2022-07-14 /pmc/articles/PMC9330335/ /pubmed/35912195 http://dx.doi.org/10.3389/fonc.2022.930125 Text en Copyright © 2022 Zhu, Zhang, Peng, Xie, Wang and Lan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhu, Ruirui Zhang, Fangyuan Peng, Yudong Xie, Tian Wang, Yi Lan, Yin Current Progress in Cancer Treatment Using Nanomaterials |
title | Current Progress in Cancer Treatment Using Nanomaterials |
title_full | Current Progress in Cancer Treatment Using Nanomaterials |
title_fullStr | Current Progress in Cancer Treatment Using Nanomaterials |
title_full_unstemmed | Current Progress in Cancer Treatment Using Nanomaterials |
title_short | Current Progress in Cancer Treatment Using Nanomaterials |
title_sort | current progress in cancer treatment using nanomaterials |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330335/ https://www.ncbi.nlm.nih.gov/pubmed/35912195 http://dx.doi.org/10.3389/fonc.2022.930125 |
work_keys_str_mv | AT zhuruirui currentprogressincancertreatmentusingnanomaterials AT zhangfangyuan currentprogressincancertreatmentusingnanomaterials AT pengyudong currentprogressincancertreatmentusingnanomaterials AT xietian currentprogressincancertreatmentusingnanomaterials AT wangyi currentprogressincancertreatmentusingnanomaterials AT lanyin currentprogressincancertreatmentusingnanomaterials |